NCT06656442CompletedPhase 3
"The Effect of Trimetazidine on the Clinical Outcome of Acute Ischemic Stroke Patients"
Source: ClinicalTrials.gov · Last updated 8 Sept 2025
Brief summary (registry, in English)
The investigators need to test the effect of Trimetazidine on the pro-inflammatory marker Interleukin - 18 , NIHSS score, and mRs score of acute ischemic stroke patients.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- First submitted
- 21 Oct 2024
- Start date
- 1 Sept 2024
- Primary completion date
- 28 Feb 2025
- Lead sponsor
- Ain Shams University
- Diseases
- Stroke
- NCT number
- NCT06656442
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 60
- From 1 Sept 2024 to the primary completion date, 28 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Contraindications of trimetazidine such as hypersensitivity to TMZ, Parkinson's disease, tremors, restless leg syndrome, or other movement disorders
Lab values
- Patients with impaired liver function are defined as INR of 1.5 or higher, elevated AST and ALT more than 3 times the upper normal limit, thrombocytopenia with platelets, 150, 000 in a patient without cirrhosis or preexisting liver disease.
- Patients with inadequate renal function defined as creatinine clearance of 60 mls/min or less
Other
- Thrombolysis-eligible patients
- Patients already on Trimetazidine for any other indication
- Patients who are NPO
- Pregnancy and lactation
Who the study is looking for
- Adult patients (≥18 years old) admitted to the stroke unit with a diagnosis of acute ischemic stroke by CT scan after excluding hemorrhagic stroke
- Patients with an NIHSS score between 5 and 25
- Within 6 - 12 hours from the initial symptoms presentation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ain Shams University Hospital Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.